<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> is a major risk factor of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e>, the role of serum total cholesterol (Chol) especially <z:chebi fb="15" ids="39026">LDL</z:chebi>-Chol is well established in the pathogenesis of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Use of cholesterol lowering drugs within the first 24 h of hospitalization for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) is associated with a lower rate of cardiogenic shock, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> and recurrent <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed data of 416 patients admitted to hospital with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> in a 2 year period (2001-2003) focusing on <z:chebi fb="0" ids="35664">statin</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>We have not found a correlation between serum <z:chebi fb="23" ids="18059">lipid</z:chebi> parameters and mortality of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:chebi fb="0" ids="35664">statin</z:chebi> treatment used before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> (in 36 patients) did not influence mortality of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Chol level of patients with ST-elevation <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e>) was significantly higher (p = 0,043) </plain></SENT>
<SENT sid="6" pm="."><plain>Mortality of patients who did not receive <z:chebi fb="0" ids="35664">statin</z:chebi> treatment after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> was significantly higher </plain></SENT>
<SENT sid="7" pm="."><plain>These data highlight the importance of early aggressive <z:chebi fb="0" ids="35664">statin</z:chebi> treatment in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> and necessity of <z:chebi fb="0" ids="35664">statins</z:chebi> in patients with <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> </plain></SENT>
</text></document>